Convalescent plasma as an adjunctive treatment for severe and critically ill COVID-19

被引:2
作者
Santosa, Damai [1 ,2 ]
Sofro, Muchlis Achsan Udji [2 ,3 ]
Retnaningsih [2 ,4 ,5 ]
Pangarsa, Eko Adhi [1 ,2 ]
Setiawan, Budi [1 ,2 ]
Farhanah, Nur [1 ,2 ]
Kholis, Fathur Nur [2 ,6 ]
Handoyo, Thomas [2 ,6 ]
Rahardjo, Sofyan [7 ]
Nindhita, Like Rahayu [8 ]
Puspitasari, Iva [9 ]
Nalbaho, Ridho M. [1 ,2 ]
Kharismasari, Retty [2 ,3 ]
Kartiyani, Ika [1 ,2 ]
Yunarvika, Vina [1 ,2 ]
Rizky, Daniel [1 ,2 ]
Suhartono [10 ]
机构
[1] Univ Diponegoro, Dept Internal Med, Fac Med, Div Hematol & Med Oncol, Semarang, Indonesia
[2] Dr Kariadi Hosp, Semarang, Indonesia
[3] Univ Diponegoro, Fac Med, Dept Intema & Med, Div Infect & Trop Dis, Semarang, Indonesia
[4] Univ Diponegoro, Fac Med, Dept Neurol, Semarang, Indonesia
[5] Dr Kariadi Hosp, Intens Care Dept, Semarang, Indonesia
[6] Univ Diponegoro, Fac Med, Dept Internal Med, Div Pulm Dis & Crit Care Med, Semarang, Indonesia
[7] Dr Kariadi Hosp, Pulmonol Dept, Semarang, Indonesia
[8] Dr Kariadi Hosp, Dept Clin Lab, Blood Transfus Unit, Semarang, Indonesia
[9] Dr Kariadi Hosp, Dept Clin Microbiol, Semarang, Indonesia
[10] Univ Diponegoro, Fac Publ Hlth, Semarang, Indonesia
关键词
Adjunctive treatment; convalescent plasma therapy; COVID-19;
D O I
10.15562/bmj.v10i3.2590
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The historical treatment of convalescent plasma was successful against RNA viruses. However, the significance of COVID-19 convalescent plasma therapy has not been clinically proven consistently in most studies and the available data showed contradictory results so far. Our study aims to evaluate the role of convalescent plasma therapy as an adjunctive treatment for severe and critically ill COVID-19 patients. Methods: This study was an open-label, non-randomized comparative clinical trial that was conducted at Dr. Kariadi Hospital, Semarang, Indonesia. This study sample are hospitalized severe and critically ill COVID-19 patients were assigned with a 2:1 ratio to receive convalescent plasma and local standard of care. The primary outcome was the clinical status 30 days after the intervention Results: A total of 73 patients received convalescent plasma and 38 patients received local standards of care. Both of the groups had similar clinical ordinal scales (median was 5, p=0.65), while patients in the study groups had significantly higher SOFA scores and P/F ratio. The control group had a worse overall mortality rate (61.1% vs 18.4%) with a hazard ratio of 3.5 (95%CI, 2.1-5.9) compared to the study group. From the subgroup analysis, we found that patients in the study group without mechanical ventilation support had the best survival rate compared to other groups HR: 0.0047 (95%CI, 0.01-0.19). The clinical outcome 7 days after convalescent plasma infusion was also significantly improved in the study group (median baseline & day-7, 5 & 3, p<0.001). From the multivariate analysis of therapeutic variables, convalescent plasma was the most significant variable for survival outcome (OR=0.089, 95%CI, 0.029-0.27; p<0.001). There was one case of anaphylactic shock and was excluded. Conclusions: The convalescent plasma administration significantly improved clinical outcomes and overall survival rates compared to those who received local standards of care.
引用
收藏
页码:851 / 859
页数:9
相关论文
共 36 条
[1]   COVID-19 convalescent plasma composition and immunological effects in severe patients [J].
Acosta-Ampudia, Yeny ;
Monsalve, Diana M. ;
Rojas, Manuel ;
Rodriguez, Yhojan ;
Esteban Gallo, Juan ;
Carlos Salazar-Uribe, Juan ;
Jose Santander, Maria ;
Cala, Monica P. ;
Zapata, Wildeman ;
Isabel Zapata, Maria ;
Manrique, Ruben ;
Mauricio Pardo-Oviedo, Juan ;
Camacho, Bernardo ;
Ramirez-Santana, Carolina ;
Anaya, Juan-Manuel .
JOURNAL OF AUTOIMMUNITY, 2021, 118
[2]   Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [J].
Agarwal, Anup ;
Mukherjee, Aparna ;
Kumar, Gunjan ;
Chatterjee, Pranab ;
Bhatnagar, Tarun ;
Malhotra, Pankaj .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
[3]   What do we know about the antibody responses to SARS-CoV-2? [J].
Alejandro Lagunas-Rangel, Francisco ;
Chavez-Valencia, Venice .
IMMUNOBIOLOGY, 2021, 226 (02)
[4]  
[Anonymous], 2020, Coronavirus Disease 2019 Guidelines
[5]  
Ariawan I, 2020, ACTA MED INDONES, V52, P193
[6]  
Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
[7]   Treatment of COVID-19: old tricks for new challenges [J].
Cunningham, Anne Catherine ;
Goh, Hui Poh ;
Koh, David .
CRITICAL CARE, 2020, 24 (01)
[8]   Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial [J].
Dastan, Farzaneh ;
Nadji, Seyed Alireza ;
Saffaei, Ali ;
Marjani, Majid ;
Moniri, Afshin ;
Jamaati, Hamidreza ;
Hashemian, Seyed MohammadReza ;
Baghaei, Parvaneh ;
Abedini, Atefeh ;
Varahram, Mohammad ;
Yousefian, Sahar ;
Tabarsi, Payam .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 85
[9]   Effectiveness of convalescent plasma therapy in severe COVID-19 patients [J].
Duan, Kai ;
Liu, Bende ;
Li, Cesheng ;
Zhang, Huajun ;
Yu, Ting ;
Qu, Jieming ;
Zhou, Min ;
Chen, Li ;
Meng, Shengli ;
Hu, Yong ;
Peng, Cheng ;
Yuan, Mingchao ;
Huang, Jinyan ;
Wang, Zejun ;
Yu, Jianhong ;
Gao, Xiaoxiao ;
Wang, Dan ;
Yu, Xiaoqi ;
Li, Li ;
Zhang, Jiayou ;
Wu, Xiao ;
Li, Bei ;
Xu, Yanping ;
Chen, Wei ;
Peng, Yan ;
Hu, Yeqin ;
Lin, Lianzhen ;
Liu, Xuefei ;
Huang, Shihe ;
Zhou, Zhijun ;
Zhang, Lianghao ;
Wang, Yue ;
Zhang, Zhi ;
Deng, Kun ;
Xia, Zhiwu ;
Gong, Qin ;
Zhang, Wei ;
Zheng, Xiaobei ;
Liu, Ying ;
Yang, Huichuan ;
Zhou, Dongbo ;
Yu, Ding ;
Hou, Jifeng ;
Shi, Zhengli ;
Chen, Saijuan ;
Chen, Zhu ;
Zhang, Xinxin ;
Yang, Xiaoming .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (17) :9490-9496
[10]  
ECDC, 2020, EPIDEMIOLOGY, P1